Inflammation and Metabolic Syndrome Dynamics

The interplay between inflammatory processes and metabolic syndrome represents a dynamic interface in which immune mediators and metabolic pathways converge to drive cardiometabolic risk. At its core, metabolic syndrome encompasses central adiposity, dyslipidaemia, hypertension and hyperglycaemia, all of which are exacerbated by a state of chronic low-grade inflammation. Adipose tissue functions not only as an energy reserve but also as an endocrine organ that secretes adipokines and pro-inflammatory cytokines. In conditions of nutrient excess, hypertrophic adipocytes release elevated levels of interleukin-6, tumour necrosis factor-α and C-reactive protein, recruiting immune cells and perpetuating insulin resistance. This inflammation impairs endothelial function and accelerates atherogenesis, thereby linking metabolic alterations to cardiovascular disease. Recent advances elucidate how shifts in adipokine balance—particularly between leptin and adiponectin—modulate glucose and lipid homeostasis, while hepatic and skeletal-muscle inflammation disrupt insulin signalling via serine phosphorylation of key receptors. Therapeutic strategies aimed at dampening inflammasome activity, restoring adipokine equilibrium and improving insulin sensitivity offer promise in attenuating the progression of metabolic syndrome and its sequelae.

Research from Nature Portfolio

Recent studies have characterised distinct obesity phenotypes in relation to inflammatory mediators. Analysis of metabolically healthy and unhealthy obesity revealed that individuals with metabolic syndrome exhibit elevated leptin and reduced adiponectin concentrations, correlating respectively with indices of insulin resistance and dyslipidaemia. Multivariable regression demonstrated that systolic blood pressure, triglycerides and low-density lipoprotein cholesterol independently predicted adiponectin levels, while body mass index was the main determinant of leptin. These findings underscore the pivotal role of adipokine dysregulation in mediating inflammatory and metabolic disturbances in obesity-related metabolic syndrome.

Inflammation and Metabolic Syndrome Dynamics publication trend

The graph below shows the total number of articles in inflammation and metabolic syndrome dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Adipokine: Bioactive peptides secreted by adipose tissue that modulate metabolism and inflammation.

Cytokine: Signalling proteins released by immune cells and adipocytes to regulate inflammatory and immune responses.

Insulin resistance: A physiological condition in which cells fail to respond effectively to insulin, impairing glucose uptake.

Chronic low-grade inflammation: A sustained, modest elevation of inflammatory mediators that contributes to metabolic and vascular dysfunction.

Metabolic syndrome: A cluster of interrelated metabolic risk factors—central obesity, dyslipidaemia, hypertension and hyperglycaemia—that increase cardiovascular risk.

Inflammasome: A multiprotein complex that activates inflammatory caspases and cytokines in response to metabolic stress.

References

1. Correlation analysis of obesity phenotypes with leptin and adiponectin. Scientific Reports (2023).
2. Serum Levels of Proinflammatory Biomarkers in Military Recruits with and without Metabolic Syndrome. Mediators of Inflammation (2023).
3. Could Tumor Necrosis Factor Serve as a Marker for Cardiovascular Risk Factors and Left Ventricular Hypertrophy in Patients with Early-Onset Coronary Artery Disease?. Diagnostics (2024).
4. Inflammation as a Link between Obesity and Metabolic Syndrome. Journal of Nutrition and Metabolism (2012).
5. Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances. F1000Research (2016).